Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04114292 · ClinicalTrials.gov registry record · Phase 1
TUDCA as a Therapy for Ulcerative Colitis (UC)
A Phase 1 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT04114292 is a Phase 1 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 14 participants.
The verdict
NCT04114292, a Phase 1 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
This is a Phase I open label study examining the efficacy and safety of TUDCA (tauroursodeoxycholic acid) in ulcerative colitis treatment.
Interventions
- DRUG Tauroursoursodeoxycholic acid, brand name Tudcabil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2019-01-17 |
| Est. Completion | 2022-06-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04114292
The ClinicalTrials.gov registry entry for NCT04114292 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tauroursoursodeoxycholic acid, brand name Tudcabil is the first listed.
NCT04114292 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04114292 about?
NCT04114292 is a clinical study titled "TUDCA as a Therapy for Ulcerative Colitis (UC)". This is a Phase I open label study examining the efficacy and safety of TUDCA (tauroursodeoxycholic acid) in ulcerative colitis treatment.
What is the current status of trial NCT04114292?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2019-01-17. Estimated completion is 2022-06-07.
What interventions are being tested in trial NCT04114292?
The interventions under investigation include: Tauroursoursodeoxycholic acid, brand name Tudcabil (DRUG).
Who is sponsoring clinical trial NCT04114292?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.